Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 3:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 16,855 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Tract Disease Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Viral Infections in Healthy and Immunocompromised Hosts

NCT01306084
View directory record Official record
Conditions
Anogenital Herpes, COVID-19, Herpes Labialis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)

NCT02008578
View directory record Official record
Conditions
Influenza
Interventions
Intravenous hyperimmune immunoglobulin (Flu-IVIG), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 4 Interventional

Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine

NCT00637585
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Not applicable Interventional

The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study

NCT00739115
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Heliox gas
Other
Lead sponsor
Hawaii Pacific Health
Other
Eligibility
1 Minute to 12 Hours
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 3 Interventional Results available

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729606
View directory record Official record
Conditions
Covid19
Interventions
Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Subjective Sleep Study of a Prototype Nasal Dilator

NCT01122849
View directory record Official record
Conditions
Sleep Disorders, Congestion, Nasal
Interventions
Prototype Nasal Dilator, Marketed Nasal Strip, Placebo Nasal Strip
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Paramus, New Jersey • Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 3 Interventional

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

NCT00135876
View directory record Official record
Conditions
Venous Thromboembolism, Brain Tumors
Interventions
dalteparin
Drug
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Evanston, Illinois • Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2007 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome

NCT02421276
View directory record Official record
Conditions
Down Syndrome, Polyendocrinopathies, Autoimmune, Respiratory Tract Infections, Autoimmunity
Interventions
Phlebotomy
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 22 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Not applicable Interventional Results available

Thrombelastography Based Dosing of Enoxaparin

NCT00990236
View directory record Official record
Conditions
Thromboembolic Complications
Interventions
Enoxaparin dose adjusted Lovenox based on TEG, Enoxaparin 30 mg BID
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Portland, Oregon • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

NCT05241834
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Interventions
LOXO-260
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 3:42 PM EDT
Terminated Phase 3 Interventional

Mycophenolate for Pulmonary Sarcoidosis

NCT00262132
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
Mycophenolate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

NCT05027932
View directory record Official record
Conditions
Influenza
Interventions
IN Placebo, IM Placebo, BPL-1357
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Not applicable Interventional Results available

Intermittent Hypoxia to Enhance Motor Function After Spinal Cord Injury

NCT03071393
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Hypoxia via Hypoxico Hyp-123, Sham via Hypoxico Hyp-123
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Results available

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

NCT03156114
View directory record Official record
Conditions
Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
Ezabenlimab, BI 754111
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Miami, Florida • Sarasota, Florida • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 2 Interventional

An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00052052
View directory record Official record
Conditions
Lung Disease, Pulmonary Fibrosis
Interventions
interferon-gamma 1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
20 Years to 79 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis

NCT00988247
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Beclomethasone dipropionate, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
34
States / cities
Oxford, Alabama • Encinitas, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 15, 2026, 3:42 PM EDT
Terminated Phase 1 Interventional Results available

Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

NCT02919449
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Cancer
Interventions
MV-NIS, Atezolizumab
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 15, 2026, 3:42 PM EDT
Not listed Phase 2Phase 3 Interventional

Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease

NCT01721655
View directory record Official record
Conditions
Chronic Lung Disease, Bronchopulmonary Dysplasia
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
West Virginia University Healthcare
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects

NCT01706315
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK2140944, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Results available

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05014815
View directory record Official record
Conditions
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
Interventions
Ociperlimab, Tislelizumab, Carboplatin, Paclitaxel, Nab paclitaxel, Cisplatin, Pemetrexed, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Iowa City, Iowa • Las Vegas, Nevada + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 15, 2026, 3:42 PM EDT
Terminated Not applicable Interventional Results available

Expiratory Muscle Strength Training and Phonation Resistance Training Exercises For Elderly Patients With Vocal Fold Atrophy

NCT03696576
View directory record Official record
Conditions
Voice Disorder, Vocal Cord Atrophy, Presbyphonia
Interventions
EMST, PhoRTE
Device · Behavioral
Lead sponsor
Emory University
Other
Eligibility
65 Years to 95 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 1Phase 2 Interventional

Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT01710644
View directory record Official record
Conditions
Pancreatic Insufficiency, Cystic Fibrosis, Digestive System Diseases, Lung Diseases, Respiratory Tract Diseases
Interventions
Burlulipase, Placebo (Caramel in sterile water)
Drug
Lead sponsor
Nordmark Arzneimittel GmbH & Co. KG
Industry
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
9
States / cities
Jacksonville, Florida • Pensacola, Florida • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Not applicable Interventional Results available

COVID-19 Watch + COVID-19 Pulse

NCT04581863
View directory record Official record
Conditions
Covid19
Interventions
pulse oximeter, COVID Watch
Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 15, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Results available

A Study for Participants With Small-Cell Lung Cancer

NCT01025284
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
LY2523355, Granulocyte colony-stimulating factor (G-CSF)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Torrington, Connecticut • Athens, Georgia • Marietta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 15, 2026, 3:42 PM EDT